Beaumont

Beaumont Laboratory Dearborn-Taylor-Trenton-Wayne

Maternal Serum Screening Report

Effective Date: December 6, 2021

Laboratory Bulletin

- Effective Monday, December 6th, the maternal serum AFP screen and the Quad screen will be performed and reported from Clinical Pathology, Royal Oak. First trimester screens will continue to be reported from Royal Oak.
- Reports will be generated from Alpha software, rather than Robert Maciel software currently used at Dearborn. The Alpha report format will differ from the current Dearborn report, however the key information will still be included. Examples are shown on the reverse of this bulletin.

General information on reporting is as follows:

- Serum marker and NT MoM's and risk assessments will be available in Epic-Beaker.
- The complete report will still include patient information used to calculate risk assessments, such as LMP, gestational age, weight, diabetic status, race, smoking history, etc.
- Abnormal reports will to be called and faxed as soon as possible after report review.
- Epic EMR users will still be able to view a scanned copy of the original report in Epic and will also receive a FAX copy, but no follow-up phone-call.
- Non-Epic EMR users will <u>not</u> have the scanned report available to them but will receive a FAX of the complete report, but no follow-up phone call.
- Criteria used to indicate increased risks:

ONTD risk	AFP MoM > 2.2
Down syndrome risk in 2 nd trimester	1:270
Down syndrome risk in 1 st trimester	1:230
Trisomy 18 risk	1:100

Date submitted: December 1, 2021

Submitted by: Elizabeth Sykes MD, System Medical Director, Clinical Chemistry

Steven Truscott, Technical Director, Special Chemistry

Beaumont

Beaumont Laboratory Dearborn-Taylor-Trenton-Wayne

Increased Risk for ONTD:

Report dated Nov 29 21 NEURAL TUBE DEFECT SCREENING : 07/28/21 EXAMPLE LMP Last name : 04/18/22 : 11/26/21 Patient EDD First name ID number Date of sample Date of birth Accession number 2T CLINICAL DETAILS AND TEST RESULTS None Previous NTD Previous Down's None Insulin dependent diabetes None No Smoker 34.6 years Maternal age at EDD : Not known : 17 weeks 2 days (by dates) 19 weeks 4 days (by scan) Scan measure Gestation at date of sample : Scan estimate : 197 lbs Gestation used Weight : non-Black Ethnic group MS-AFP level : 121.0 ng/mL ; 2.60 MoM

INTERPRETATION

Screening result : *** SCREEN POSITIVE ***

Reason : Raised AFP Risk of NTD : 1 in 65

Comment : The interpretation is for NTD only

COMMENTS FROM William Beaumont Hospital

This result, based on ultrasound dating, is screen positive for an increased risk of open neural tube defect. Genetic counseling to discuss level 2 ultrasound and diagnostic testing is recommended.

Increased Risk for Down Syndrome but NOT increased for ONTD:

DOWN'S SYNDROME AND NEURAL TUBE DEFECT SCREENING Report dated Nov 29 21 Last name : PATIENT : 07/28/21 First name ID number : Example EDD : 05/04/22 : 11/23/21 Date of sample Date of birth Accession number 2T CLINICAL DETAILS AND TEST RESULTS Previous NTD : None Previous Down's None Insulin dependent diabetes None No 39.7 years Maternal age at EDD Not known 16 weeks 6 days (by dates) 16 weeks 6 days (by scan) Scan estimate Scan measure Gestation at date of sample Gestation used Weight Ethnic group MS-AFP level uE3 level Total hCG level 188 lbs : Black : 33.0 ng/mL : 1.78 ng/mL : 75.00 IU/mL ; 0.86 MoM ; 1.81 MoM ; 2.05 MoM Inhibin-A level : 304.1 pg/mL ; 2.40 MoM INTERPRETATION : *** SCREEN POSITIVE *** Screening result : Increased risk of Down's syndrome : 1 in 160 : 1 in 7,000 Reason Risk of Down's Risk of NTD The risk of Down's is lower than that expected from the maternal age alone (1 in 80): Trisomy 18 risk: 1 in 15,000 Comment Comment

COMMENTS FROM William Beaumont Hospital

This result, based on ultrasound dating, is screen positive for an increased risk of Down syndrome. Genetic counseling to discuss diagnostic testing is recommended.